Prestige Consumer Healthcare Inc

Latest Results (17.05.2026):

Prestige Consumer Healthcare Inc. reported results for the third quarter of fiscal 2026 (Q3 FY2026). GAAP revenue was $283.4 million (down 2.4% year‑over‑year), net income was $46.7 million (diluted EPS $0.97), and Non‑GAAP adjusted diluted EPS was $1.14. The company closed the Pillar5 Pharma acquisition in December, repurchased roughly 0.8 million shares in Q3, and narrowed its FY2026 outlook while projecting improved Clear Eyes® supply in coming quarters.

Revenue

Q3 FY2026 GAAP total revenue: $283.4 million, a 2.4% decline versus Q3 FY2025. Non‑GAAP organic revenue decline for Q3 was slightly smaller at 2.2%.

EPS & Net Income

Q3 FY2026 net income: $46.7 million; GAAP diluted EPS: $0.97 (vs. $1.22 in prior-year Q3). Non‑GAAP adjusted diluted EPS for Q3 was $1.14 after adjustments (supplier loan write‑off and acquisition-related costs).

EBITDA & Margins

Q3 FY2026 Non‑GAAP EBITDA was $80.1 million (28.3% margin). After adjustments (write‑off and acquisition costs) adjusted EBITDA rose to $90.9 million with a 32.1% margin.

Cash Flow & Balance Sheet

Nine months ended FY2026: net cash provided by operating activities was $214.8 million and Non‑GAAP free cash flow was $208.8 million. Cash and cash equivalents at period end were $62.4 million. Net debt (total principal $1,040.0M less cash) is roughly $977.6 million.

Share Repurchases

The company opportunistically repurchased approximately 0.8 million shares in Q3. Year‑to‑date repurchases (nine months) totaled about $155.6 million.

Acquisition & One‑time Items

Prestige closed the Pillar5 Pharma acquisition in December 2025. Q3 adjustments included a $10.332 million supplier loan write‑off and $0.472 million of acquisition‑related professional costs (both affect non‑GAAP adjustments).

Outlook

Management narrowed FY2026 guidance: organic revenue is expected to decline roughly 3.0% (current outlook), projected FY2026 GAAP diluted EPS is $4.16 with projected Non‑GAAP adjusted diluted EPS of $4.54. Projected FY2026 GAAP net cash provided by operating activities is ~$255 million and projected Non‑GAAP free cash flow ~$245 million.

Segment Performance

Q3 FY2026 segment revenues: North American OTC $235.7 million and International OTC $47.7 million. For the first nine months, North American OTC was $679.0 million and International OTC was $128.1 million (down ~1.6% year‑over‑year, or ~0.9% excl. FX).